Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30

$6.96−0.22 (-3.06%)

Close on Nov 13, 2026Market cap $459.71MP/E –Yield –

Evolus profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Evolus's profit margin for the twelve months ending Sep 30, 2026 was -9.6%. For fiscal 2025 it was -17.4%, against -18.9% the year before. The highest annual figure on record is -17.4% in fiscal 2025.

Annual profit margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-17.4%	+1.6
FY2024	Dec 31, 2024	-18.9%	+11.6
FY2023	Dec 31, 2023	-30.5%	+19.5
FY2022	Dec 31, 2022	-50.1%	−3.1
FY2021	Dec 31, 2021	-47.0%	+241.4
FY2020	Dec 31, 2020	-288.3%	−30.5
FY2019	Dec 31, 2019	-257.8%	–

Quarterly profit margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-16.1%	+6.8
Q2 FY2026	Jun 30, 2026	-9.6%	+15.1
Q1 FY2026	Mar 31, 2026	-14.6%	+13.0
Q4 FY2025	Dec 31, 2025	0.1%	+8.7
Q3 FY2025	Sep 30, 2025	-22.8%	+8.6
Q2 FY2025	Jun 30, 2025	-24.7%	−7.7
Q1 FY2025	Mar 31, 2025	-27.6%	−5.5
Q4 FY2024	Dec 31, 2024	-8.6%	+10.8
Q3 FY2024	Sep 30, 2024	-31.4%	+2.5
Q2 FY2024	Jun 30, 2024	-17.0%	+19.8
Q1 FY2024	Mar 31, 2024	-22.1%	+13.4
Q4 FY2023	Dec 31, 2023	-19.4%	+10.8
Q3 FY2023	Sep 30, 2023	-33.8%	+26.0
Q2 FY2023	Jun 30, 2023	-36.8%	+26.4
Q1 FY2023	Mar 31, 2023	-35.5%	+16.2
Q4 FY2022	Dec 31, 2022	-30.2%	+22.3
Q3 FY2022	Sep 30, 2022	-59.8%	+13.0
Q2 FY2022	Jun 30, 2022	-63.2%	−3.4
Q1 FY2022	Mar 31, 2022	-51.6%	−103.9
Q4 FY2021	Dec 31, 2021	-52.4%	+485.5
Q3 FY2021	Sep 30, 2021	-72.8%	−8.0
Q2 FY2021	Jun 30, 2021	-59.8%	+210.8
Q1 FY2021	Mar 31, 2021	52.3%	+240.3
Q4 FY2020	Dec 31, 2020	-538.0%	−463.3
Q3 FY2020	Sep 30, 2020	-64.9%	+140.1
Q2 FY2020	Jun 30, 2020	-270.6%	+1354.9
Q1 FY2020	Mar 31, 2020	-188.0%	–
Q4 FY2019	Dec 31, 2019	-74.6%	–
Q3 FY2019	Sep 30, 2019	-204.9%	–
Q2 FY2019	Jun 30, 2019	-1625.6%	–